Montgomery Investment Management Inc. Has $429,000 Position in Pfizer Inc. $PFE

Montgomery Investment Management Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 4.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,701 shares of the biopharmaceutical company’s stock after selling 800 shares during the quarter. Montgomery Investment Management Inc.’s holdings in Pfizer were worth $429,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. CHURCHILL MANAGEMENT Corp increased its position in shares of Pfizer by 13.5% during the 2nd quarter. CHURCHILL MANAGEMENT Corp now owns 371,083 shares of the biopharmaceutical company’s stock worth $8,995,000 after purchasing an additional 44,218 shares in the last quarter. Philip James Wealth Mangement LLC increased its holdings in shares of Pfizer by 20.3% during the second quarter. Philip James Wealth Mangement LLC now owns 398,719 shares of the biopharmaceutical company’s stock worth $9,665,000 after buying an additional 67,253 shares in the last quarter. Pure Financial Advisors LLC increased its holdings in Pfizer by 38.5% during the 2nd quarter. Pure Financial Advisors LLC now owns 33,041 shares of the biopharmaceutical company’s stock valued at $801,000 after purchasing an additional 9,183 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in Pfizer by 36.6% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 10,151,483 shares of the biopharmaceutical company’s stock valued at $246,072,000 after purchasing an additional 2,720,184 shares in the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. increased its holdings in Pfizer by 1.9% during the 2nd quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 522,094 shares of the biopharmaceutical company’s stock valued at $12,656,000 after purchasing an additional 9,592 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 6.8%

Shares of NYSE:PFE opened at $27.21 on Thursday. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a 50 day moving average of $24.59 and a 200-day moving average of $24.14. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a market cap of $154.68 billion, a price-to-earnings ratio of 14.47, a P/E/G ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the company earned $0.60 EPS. Pfizer’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on PFE shares. Bank of America raised their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Citigroup raised their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. UBS Group restated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Morgan Stanley raised their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.29.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.